phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
Published 1 year ago • 107 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
14:29
fa connect: stanford fanconi anemia (fa) program & clinical trials
-
54:24
controversy: dual vs triple antithrombotic therapy in af patients undergoing pci. what’s best?
-
17:11
juan fortea: cerebrospinal fluid b-amyloid and phospho-tau biomarker interactions
-
41:33
[efficacy] e2b(r3)
-
4:28
first-in-human study of tnb-383b, a bcma x cd3 bispecific t-cell redirecting antibody, in pts w/rrmm
-
1:03:59
endogenous retrovirus control of host skin immunity - djalma de souza lima júnior - fmrp-usp
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
2:37
exploratory analysis of frontline therapies in revel: phase 3 trial of ramucirumab in nsclc
-
47:15
2d to 3d ebrt | session 11 | reviewing portal images (practical basic cases)
-
4:06
overall survival results from bellini, venetoclax or placebo in comb w/ bortezomib and dex in rrmm
-
9:59
what does a regulatory t cell (treg) do?
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
2:36:45
world alergy week - module 3 - in english
-
1:13:17
2d to 3d ebrt | session 16 | evaluating normal tissue constraints and plans for treatment
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
3:53
b-cell maturation antigen targeted cd3-engaging bispecific molecule for relapsed or refractory m...
-
4:34
influenza and community-acquired pneumonia lo 3
-
44:35
v semana de biomedicina
-
3:41
teclistamab: bcma x cd3 bispecific antibody in rrmm
-
1:43
gilteritinib monotherapy vs combination therapy in r/r flt3-mutated aml
-
1:44
dr. koprivnikar discusses flt3 inhibitors in hematologic malignancies
-
51:24
immunosuppression via effeocytosis in the tumor microenvironment